BAD HOMBURG, Germany, Nov. 25, 2021 /PRNewswire=KYODO JBN/--
Fresenius Kabi was delighted to announce the winner of their innovative
JUMPstart education program and research grant on September 10, 2021. JUMPstart
is an initiative that aims to nurture research in the field of parenteral
nutrition through the mentoring, education and networking of clinicians and
researchers. The grant is awarded to help to advance novel, community-led
research in parenteral nutrition, to make a difference for critically ill
This year's winner is Professor Stefan Schaller M.D. of Charite –
Universitatsmedizin Berlin, Germany, for his proposal entitled "Improved muscle
metabolism by combination of muscle activation and protein substitution." This
cutting-edge study aims to explore the effect of protein substitution before
and after early, goal-directed mobilization in the acute phase of critical
illness. The announcement was made at the European Society for Clinical
Nutrition and Metabolism (ESPEN) Congress.
During the virtual awards ceremony, Professor Schaller said: "After working on
this research proposal for a long time, me and my research team are thrilled to
be able to now conduct the study, and I am very thankful to the generous grant
from Fresenius Kabi. I am very optimistic that this trial will have an impact
on nutrition therapy in critical care."
Professor Schaller took part in the program alongside 18 other participants
from around the world, including representation from Africa, Asia, Australia,
Europe, New Zealand, and North and South America. After four training sessions,
participants presented their research proposals to an independent international
scientific committee, which consisted of five field-leading experts: Professor
Mette Berger, Switzerland; Professor Olav Rooyackers, Sweden; Professor Tim
Friede, Germany; Professor Robert Martindale, USA; and Professor Ho-Seong Han,
South Korea. The committee was impressed by the high-quality level of all
proposals, and this made picking a winner extremely challenging.
Dr. Jos Simons, Executive Vice President at Fresenius Kabi, commented: "We are
absolutely delighted to be able to award this research grant to Professor
Schaller. Both the scientific committee and Fresenius Kabi were astounded by
his proposal and the positive impact it will have on clinical practice. We are
very excited for Professor Schaller to start this clinical study."
This is the second JUMPstart research grant worth Euro 250,000. The first
program of 19 participants completed in 2019, with the grant awarded to
dietician Lizl Veldsman, Tygerberg Academic Hospital in Cape Town, South
With the JUMPstart education program and research grant, Fresenius Kabi
supports the next generation of clinical experts who will contribute to
advancement in nutrition therapy in critically ill patients.
Fresenius Kabi is a global healthcare company that specializes in lifesaving
medicines and technologies for infusion, transfusion and clinical nutrition.
The company's products and services are used to help care for critically and
chronically ill patients. Fresenius Kabi's product portfolio comprises a
comprehensive range of I.V. generic drugs, infusion therapies and clinical
nutrition products as well as the devices for administering these products. In
the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and
oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched.
Within transfusion medicine and cell therapies, Fresenius Kabi offers products
for collection of blood components and extracorporeal therapies.
With its corporate philosophy of "caring for life", the company is committed to
putting essential medicines and technologies in the hands of people who help
patients and finding the best answers to the challenges they face.
Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company
reported sales of around Euro 7.0 billion. Fresenius Kabi AG is a wholly owned
subsidiary of the Fresenius SE & Co. KGaA healthcare group.
For more information, please visit www.fresenius-kabi.com
This release contains forward-looking statements that are subject to various
risks and uncertainties. Future results could differ materially from those
described in these forward-looking statements due to certain factors, e.g.
changes in business, economic and competitive conditions, regulatory reforms,
results of clinical trials, foreign exchange rate fluctuations, uncertainties
in litigation or investigative proceedings, and the availability of financing.
Fresenius Kabi does not undertake any responsibility to update the
forward-looking statements in this release.
Management Board: Michael Sen (Chairman), Marc Crouton, John Ducker, Dr. Oskar
Haszonits, Dr. Christian Hauer, Dr. Michael Schonhofen, Gerrit Steen
Chairman of the Supervisory Board: Stephan Sturm
Registered Office: Bad Homburg, Germany
Commercial Register: Amtsgericht Bad Homburg - HRB 11654
Contact: Emese Kamp
PINK CARROTS Communications GmbH
Source: Fresenius Kabi